Colopredict Plus News Today

BioNTech SE: BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

October 1, 2021

Second Phase 2 trial initiated from BioNTech's proprietary individualized mRNA-based cancer vaccine platform iNeST Randomized Phase 2 trial will enroll approximately 200 patients with high-risk colorectal

United States Sylke Maas Fosun Pharma Association For Internal Oncology Bayer Animal Health Ruhr University Bochum

Source: finanznachrichten.de

Navigation

Colopredict Plus News Today

Integrating AI with infrared imaging to improve colon cancer diagnosis

BioNTech SE: BioNTech Expands Clinical Oncology Portfolio with First Patient Dosed in Phase 2 Trial of mRNA-based Individualized Immunotherapy BNT122 in Colorectal Cancer Patients

Explore More Categories